Mani A Daneshmand
@drmanictsurgery
Director of Heart & Lung Transplant, MCS, & ECMO at Emory University. Tweets are my own views and not medical advice.
ID: 47885930
http://www.surgery.emory.edu/about-us/faculty_directory/faculty_profile_mani_daneshmand.html 17-06-2009 07:11:30
192 Tweet
1,1K Followers
556 Following
🔥JACC Journals #JACCHF our commentary on WHY, WHEN and HOW to use #LVAD in #HF. @MRMehraMD Akshay Desai jacc.org/doi/10.1016/j.… WHY? Advanced #HF is defined by the transition from Neurohormonal➡️invasive LAPLACE therapeutics, for which #LVAD is the only scalable therapy 1/3
Happy to share our work on mechanisms of VF in explanted human hearts. Thank you to Mani A Daneshmand for helping us with this endeavor. If you could also stop doing transplants at 3 AM, then I could get some sleep :-) tinyurl.com/2rbcbtfj Faisal Merchant Mikhael El-Chami
New #VirtualTumorBoard | Experts from Winship Cancer Institute of Emory University treat a young adult with metastatic #RenalCellCarcinoma and offer cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in this unique case. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… #TumorBoardTuesday #AACR24
Wrapped up our BrioHealth Solutions Core Training with Mani A Daneshmand and Divya Gupta, MD! Will be 1 of only 8 programs kicking off this groundbreaking clinical trial of a new MagLev LVAD system!
First BrioVAD in the U.S. just done at Emory by Mani A Daneshmand! Exciting to see a new MagLev LVAD available for patients. news.emory.edu/stories/2024/1…
Great job Joshua Chan, MD and his lab. 2 presentations at the 51st meeting of Western Thoracic Surgical Association!
ishlt.org/event-calendar… Joshua Preston is one of 5 finalist for the ISHLT Early Career Scientist Award - will be presenting our work on heart transplant PGD metabolomics!
Clinical adaptation of Organ Care System (OCS) Heart device for DBD donors with a dedicated recovery team is associated with expanded donor criteria, longer transport distance and excellent post-transplant outcomes Josef Stehlik Yasuhiro Shudo @PARAGPATELMD ahajournals.org/doi/full/10.11…
Now out in Journal of Cardiac Failure: A prospective, multi-center registry of Impella 5.5 in HF-CS: 🔗bit.ly/4j8h171 🔑 Treatment with Impella 5.5 alone vs. multiple MCSD associated with ⬆️ survival and ⬇️complications 🔑 Patients bridged to HRT have 94% survival at 12- months